← Back to Search

Tyrosine Kinase Inhibitor

TPX-0005 for Tumors

Phase 1 & 2

Waitlist Available

Research Sponsored by Turning Point Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from screening to end of treatment approximately 10 months

Awards & highlights

Study Summary

This trial is testing a new drug, repotrectinib, to see if it can help people with KRAS-mutant cancer.

Eligible Conditions

KRAS Mutation-Related Tumors
Metastatic Tumor
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from screening to end of treatment approximately 10 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from screening to end of treatment approximately 10 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and from screening to end of treatment approximately 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Dose Limiting Toxicities

Secondary outcome measures

AUC 0-24 of Repotrecitinib

AUC 0-24 of Trametinib

Cmax of Repotrectinib

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: TPX-0005 + TrametinibExperimental Treatment2 Interventions

TPX-0005 + Trametinib Dose Escalation and Dose Expansion Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Trametinib

2014

Completed Phase 2

~1550

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Turning Point Therapeutics, Inc.Lead Sponsor

9 Previous Clinical Trials

868 Total Patients Enrolled

Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb

1,507 Previous Clinical Trials

3,369,988 Total Patients Enrolled

8 Trials studying Tumors

422 Patients Enrolled for Tumors

Turning Point Therapeutics, MDStudy DirectorTurning Point Theraperutics

3 Previous Clinical Trials

127 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other TPX-0005 medical studies have taken place in the past?

"TPX-0005 is being researched in 96 different studies, 6 of which are in the final stage of clinical trials. Most of the research for TPX-0005 is conducted in Saint Louis, Missouri; however, there are 5800 locations worldwide running these medical studies."

Answered by AI

Can people with the appropriate medical conditions still sign up for this trial?

"The clinical trial was posted on September 23rd, 2021 and is not currently looking for patients. The last update to the listing was on November 7th, 2022. There are 2594 other studies involving kras mutation-related tumors that are actively recruiting patients and 96 trials for TPX-0005 also have open enrollment"

Answered by AI

How many subjects are included in this experiment?

"Presently, this study is not enrolling patients. The posting date was September 23rd 2021 with the latest update on November 7th 2022. However, there are 2594 other clinical trials for kras mutation-related tumors and 96 TPX-0005 trials that are currently looking for participants."

Answered by AI

Are there many test sites for this experiment in North America?

"MD Anderson Cancer Center in Houston, Sarah Cannon Research Institute at Tennessee Oncology in Nashville, and Sarah Cannon Research Institute at HealthONE in Denver are a few of the available sites for this study. There are also 6 other locations where patients can enroll."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

2021. "A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05071183.